Survival expressed in best-case, typical and worst-case scenarios for patients with nonmetastatic esophagogastric cancer: A population-based study
| Autor: | Steven Kuijper, Marieke Pape, Pauline A.J. Vissers, Paul M. Jeene, Ewout Kouwenhoven, Nadia Haj Mohammad, Meindert Sosef, Rob Verhoeven, Hanneke W.M. Van Laarhoven |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 40:259-259 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2022.40.4_suppl.259 |
| Popis: | 259 Background: In recent years new treatment options and the centralization of surgery have improved survival for patients with non-metastatic esophageal and gastric cancer. However, it is currently unknown which patients have mostly benefitted from these treatment advances. The aim of this study was to use population-based data to identify best-case, typical and worst-case scenarios in terms of survival time, and to assess if the survival of these scenarios have changed over time. Methods: Patients diagnosed between 2006-2019 with non-metastatic esophageal (including gastro-esophageal junction tumors) or gastric cancer were selected from the Netherlands Cancer Registry. Best-case, typical, and worst-case scenarios were calculated from the 20th (best-case scenario), 40th (upper-typical), 50th (median), 60th (lower-typical) and 80th (worst-case scenario) percentiles of the survival curves. Linear trend analysis was used to investigate the change in survival time for each scenario across diagnosis years. Results: We identified 23350 patients with non-metastatic esophageal cancer and 10150 patients with non-metastatic gastric cancer. Linear trend analyses across diagnosis years showed that for esophageal cancer patients, survival of all scenarios significantly increased over time: the best-case scenario increased from 55 to 112 months (p =.003); the upper typical increased from 18 to 33 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|